10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CGEN (Compugen) Stock Analysis
Buy, Hold or Sell?

Let's analyze Compugen together

I guess you are interested in Compugen. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Compugen’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Compugen’s Price Targets

I'm going to help you getting a better view of Compugen. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Compugen

I send you an email if I find something interesting about Compugen.

1. Quick Overview

1.1. Quick analysis of Compugen (30 sec.)










1.2. What can you expect buying and holding a share of Compugen? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
ILA198.28
Expected worth in 1 year
ILA44.53
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
ILA-153.74
Return On Investment
-26.4%

For what price can you sell your share?

Current Price per Share
ILA581.40
Expected price per share
ILA319.40 - ILA750.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Compugen (5 min.)




Live pricePrice per Share (EOD)
ILA581.40
Intrinsic Value Per Share
ILA1,680.93 - ILA3,692.73
Total Value Per Share
ILA1,879.21 - ILA3,891.01

2.2. Growth of Compugen (5 min.)




Is Compugen growing?

Current yearPrevious yearGrowGrow %
How rich?$54.9m$65.5m-$10.6m-19.4%

How much money is Compugen making?

Current yearPrevious yearGrowGrow %
Making money-$14.2m-$18.7m$4.5m31.8%
Net Profit Margin-51.1%-56.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Compugen (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#409 / 884

Most Revenue
#203 / 884

Most Profit
#590 / 884

Most Efficient
#485 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Compugen?

Welcome investor! Compugen's management wants to use your money to grow the business. In return you get a share of Compugen.

First you should know what it really means to hold a share of Compugen. And how you can make/lose money.

Speculation

The Price per Share of Compugen is ILA581.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Compugen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Compugen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA198.28. Based on the TTM, the Book Value Change Per Share is ILA-38.44 per quarter. Based on the YOY, the Book Value Change Per Share is ILA-43.77 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Compugen.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps-0.150.0%-0.150.0%-0.200.0%-0.240.0%-0.280.0%-0.290.0%
Usd Book Value Change Per Share-0.110.0%-0.110.0%-0.130.0%-0.180.0%0.040.0%-0.050.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.110.0%-0.110.0%-0.130.0%-0.180.0%0.040.0%-0.050.0%
Usd Price Per Share1.66-1.66-2.04-1.47-3.98-4.43-
Price to Earnings Ratio-10.92--10.92--10.16--7.69--14.05--15.92-
Price-to-Total Gains Ratio-14.59--14.59--15.72--10.87--9.52-44.81-
Price to Book Ratio2.83-2.83-2.91-2.20-3.82-6.48-
Price-to-Total Gains Ratio-14.59--14.59--15.72--10.87--9.52-44.81-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.7221068
Number of shares580
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.04
Usd Total Gains Per Share-0.110.04
Gains per Quarter (580 shares)-66.0320.59
Gains per Year (580 shares)-264.1382.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-264-27408272
20-528-5380165154
30-792-8020247236
40-1057-10660329318
50-1321-13300412400
60-1585-15940494482
70-1849-18580576564
80-2113-21220659646
90-2377-23860741728
100-2641-26500823810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.012.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%3.07.00.030.0%5.07.00.041.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.012.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%3.07.00.030.0%5.07.00.041.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Compugen compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---38.436-38.4360%-43.766+14%-62.320+62%11.983-421%-18.488-52%
Book Value Per Share--198.280198.2800%236.716-16%238.492-17%306.643-35%246.578-20%
Current Ratio--5.2585.2580%4.362+21%5.615-6%7.264-28%7.912-34%
Debt To Asset Ratio--0.5220.5220%0.460+14%0.386+35%0.297+76%0.252+108%
Debt To Equity Ratio--1.0941.0940%0.851+29%0.719+52%0.510+114%0.393+178%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--32165092050.00032165092050.0000%45504515250.000-29%31551689500.000+2%113848831980.000-72%131837591490.000-76%
Eps---51.384-51.3840%-67.716+32%-80.253+56%-94.298+84%-97.219+89%
Ev To Sales Ratio--3.4193.4190%4.028-15%4.718-28%120.455-97%180.312-98%
Free Cash Flow Per Share--178.680178.6800%-130.196+173%-25.955+115%-52.784+130%-65.728+137%
Free Cash Flow To Equity Per Share--180.681180.6810%-119.071+166%-21.155+112%40.582+345%17.236+948%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3692.726----------
Intrinsic Value_10Y_min--1680.929----------
Intrinsic Value_1Y_max--59.551----------
Intrinsic Value_1Y_min--3.022----------
Intrinsic Value_3Y_max--415.554----------
Intrinsic Value_3Y_min--152.407----------
Intrinsic Value_5Y_max--1056.837----------
Intrinsic Value_5Y_min--457.727----------
Market Cap54368458200.000+4%52451441700.00052451441700.0000%64336944000.000-18%46447907100.000+13%125758152660.000-58%139745827200.000-62%
Net Profit Margin---0.511-0.5110%-0.561+10%-1.855+263%-5.223+923%-7.381+1345%
Operating Margin----0%-0%-1.5720%-5.2620%-7.3550%
Operating Ratio--1.8191.8190%1.448+26%3.038-40%6.570-72%8.572-79%
Pb Ratio2.932+4%2.8292.8290%2.906-3%2.198+29%3.815-26%6.481-56%
Pe Ratio-11.315-4%-10.916-10.9160%-10.160-7%-7.686-30%-14.046+29%-15.915+46%
Price Per Share581.400+4%560.900560.9000%688.000-18%496.700+13%1344.820-58%1494.400-62%
Price To Free Cash Flow Ratio3.254+4%3.1393.1390%-5.284+268%-1.351+143%-11.601+470%-10.381+431%
Price To Total Gains Ratio-15.126-4%-14.593-14.5930%-15.720+8%-10.872-25%-9.517-35%44.807-133%
Quick Ratio--4.2184.2180%3.723+13%4.671-10%6.336-33%6.341-33%
Return On Assets---0.124-0.1240%-0.155+25%-0.212+71%-0.222+79%-0.365+195%
Return On Equity---0.259-0.2590%-0.286+10%-0.326+26%-0.309+19%-0.485+87%
Total Gains Per Share---38.436-38.4360%-43.766+14%-62.320+62%11.983-421%-18.488-52%
Usd Book Value--54920551.24054920551.2400%65566821.189-16%66058879.884-17%84935731.624-35%68298647.057-20%
Usd Book Value Change Per Share---0.114-0.1140%-0.130+14%-0.185+62%0.035-421%-0.055-52%
Usd Book Value Per Share--0.5870.5870%0.701-16%0.706-17%0.908-35%0.730-20%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--95273002.65295273002.6520%134784374.171-29%93456104.299+2%337220240.325-72%390502945.993-76%
Usd Eps---0.152-0.1520%-0.201+32%-0.238+56%-0.279+84%-0.288+89%
Usd Free Cash Flow--49491903.68049491903.6800%-36062301.719+173%-7189190.902+115%-14620343.999+130%-14564537.342+129%
Usd Free Cash Flow Per Share--0.5290.5290%-0.386+173%-0.077+115%-0.156+130%-0.195+137%
Usd Free Cash Flow To Equity Per Share--0.5350.5350%-0.353+166%-0.063+112%0.120+345%0.051+948%
Usd Market Cap161039373.188+4%155361170.315155361170.3150%190566028.128-18%137578700.830+13%372495648.179-58%413927140.166-62%
Usd Price Per Share1.722+4%1.6611.6610%2.038-18%1.471+13%3.983-58%4.426-62%
Usd Profit---14232697.758-14232697.7580%-18756237.352+32%-22228984.935+56%-26119115.639+84%-26928312.164+89%
Usd Revenue--27867324.17527867324.1750%33462991.659-17%22943736.861+21%15366432.997+81%10462448.021+166%
Usd Total Gains Per Share---0.114-0.1140%-0.130+14%-0.185+62%0.035-421%-0.055-52%
 EOD+4 -4MRQTTM+0 -0YOY+21 -143Y+23 -125Y+15 -2010Y+15 -20

3.3 Fundamental Score

Let's check the fundamental score of Compugen based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.315
Price to Book Ratio (EOD)Between0-12.932
Net Profit Margin (MRQ)Greater than0-0.511
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.218
Current Ratio (MRQ)Greater than15.258
Debt to Asset Ratio (MRQ)Less than10.522
Debt to Equity Ratio (MRQ)Less than11.094
Return on Equity (MRQ)Greater than0.15-0.259
Return on Assets (MRQ)Greater than0.05-0.124
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Compugen based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose584.400
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naΓ―ve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Fundamental data was last updated by Penke on 2025-06-19 02:24:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Compugen earns for each 1 of revenue.

  • Above 10% is considered healthy but always compareΒ Compugen to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -51.1%Β means thatΒ -0.51 for each 1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Compugen:

  • The MRQ is -51.1%. The company is making a huge loss. -2
  • The TTM is -51.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-51.1%TTM-51.1%0.0%
TTM-51.1%YOY-56.1%+5.0%
TTM-51.1%5Y-522.3%+471.2%
5Y-522.3%10Y-738.1%+215.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51.1%-92.7%+41.6%
TTM-51.1%-141.4%+90.3%
YOY-56.1%-186.1%+130.0%
3Y-185.5%-248.3%+62.8%
5Y-522.3%-338.6%-183.7%
10Y-738.1%-488.9%-249.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Compugen is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Compugen to theΒ Biotechnology industry mean.
  • -12.4% Return on Assets means thatΒ Compugen generatedΒ -0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Compugen:

  • The MRQ is -12.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.4%TTM-12.4%0.0%
TTM-12.4%YOY-15.5%+3.1%
TTM-12.4%5Y-22.2%+9.8%
5Y-22.2%10Y-36.5%+14.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.4%-11.5%-0.9%
TTM-12.4%-11.6%-0.8%
YOY-15.5%-11.4%-4.1%
3Y-21.2%-11.8%-9.4%
5Y-22.2%-12.1%-10.1%
10Y-36.5%-13.8%-22.7%
4.3.1.3. Return on Equity

Shows how efficient Compugen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Compugen to theΒ Biotechnology industry mean.
  • -25.9% Return on Equity means Compugen generated -0.26Β for eachΒ 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Compugen:

  • The MRQ is -25.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.9%TTM-25.9%0.0%
TTM-25.9%YOY-28.6%+2.7%
TTM-25.9%5Y-30.9%+5.0%
5Y-30.9%10Y-48.5%+17.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.9%-13.6%-12.3%
TTM-25.9%-14.9%-11.0%
YOY-28.6%-14.4%-14.2%
3Y-32.6%-17.0%-15.6%
5Y-30.9%-17.9%-13.0%
10Y-48.5%-20.1%-28.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Compugen.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Compugen is operatingΒ .

  • Measures how much profit Compugen makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Compugen to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated 0.00 Β for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Compugen:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-526.2%+526.2%
5Y-526.2%10Y-735.5%+209.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--250.3%+250.3%
YOY--205.1%+205.1%
3Y-157.2%-220.2%+63.0%
5Y-526.2%-342.6%-183.6%
10Y-735.5%-475.5%-260.0%
4.3.2.2. Operating Ratio

Measures how efficient Compugen is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 1.82 means that the operating costs are 1.82 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Compugen:

  • The MRQ is 1.819. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.819. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.819TTM1.8190.000
TTM1.819YOY1.448+0.371
TTM1.8195Y6.570-4.751
5Y6.57010Y8.572-2.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8192.110-0.291
TTM1.8192.704-0.885
YOY1.4483.063-1.615
3Y3.0383.576-0.538
5Y6.5704.713+1.857
10Y8.5726.512+2.060
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Compugen.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Compugen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 5.26Β means the company has 5.26 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Compugen:

  • The MRQ is 5.258. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.258. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.258TTM5.2580.000
TTM5.258YOY4.362+0.896
TTM5.2585Y7.264-2.006
5Y7.26410Y7.912-0.648
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2583.661+1.597
TTM5.2583.786+1.472
YOY4.3624.121+0.241
3Y5.6154.680+0.935
5Y7.2645.765+1.499
10Y7.9126.150+1.762
4.4.3.2. Quick Ratio

Measures if Compugen is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Compugen to theΒ Biotechnology industry mean.
  • A Quick Ratio of 4.22Β means the company can pay off 4.22 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Compugen:

  • The MRQ is 4.218. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.218. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.218TTM4.2180.000
TTM4.218YOY3.723+0.494
TTM4.2185Y6.336-2.118
5Y6.33610Y6.341-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2182.826+1.392
TTM4.2183.128+1.090
YOY3.7233.782-0.059
3Y4.6714.304+0.367
5Y6.3365.703+0.633
10Y6.3416.454-0.113
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Compugen.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CompugenΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Compugen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.52Β means that Compugen assets areΒ financed with 52.2% credit (debt) and the remaining percentage (100% - 52.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Compugen:

  • The MRQ is 0.522. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.522. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.522TTM0.5220.000
TTM0.522YOY0.460+0.063
TTM0.5225Y0.297+0.226
5Y0.29710Y0.252+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5220.324+0.198
TTM0.5220.347+0.175
YOY0.4600.327+0.133
3Y0.3860.339+0.047
5Y0.2970.349-0.052
10Y0.2520.382-0.130
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Compugen is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Compugen to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 109.4% means that company has 1.09 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Compugen:

  • The MRQ is 1.094. The company is able to pay all its debts with equity. +1
  • The TTM is 1.094. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.094TTM1.0940.000
TTM1.094YOY0.851+0.243
TTM1.0945Y0.510+0.584
5Y0.51010Y0.393+0.117
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0940.383+0.711
TTM1.0940.436+0.658
YOY0.8510.410+0.441
3Y0.7190.446+0.273
5Y0.5100.460+0.050
10Y0.3930.509-0.116
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every 1 in earnings Compugen generates.

  • Above 15 is considered overpriced butΒ always compareΒ Compugen to theΒ Biotechnology industry mean.
  • A PE ratio of -10.92 means the investor is paying -10.92Β for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Compugen:

  • The EOD is -11.315. Based on the earnings, the company is expensive. -2
  • The MRQ is -10.916. Based on the earnings, the company is expensive. -2
  • The TTM is -10.916. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.315MRQ-10.916-0.399
MRQ-10.916TTM-10.9160.000
TTM-10.916YOY-10.160-0.756
TTM-10.9165Y-14.046+3.130
5Y-14.04610Y-15.915+1.869
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.315-2.197-9.118
MRQ-10.916-2.027-8.889
TTM-10.916-2.527-8.389
YOY-10.160-3.733-6.427
3Y-7.686-3.717-3.969
5Y-14.046-6.036-8.010
10Y-15.915-6.649-9.266
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Compugen:

  • The EOD is 3.254. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 3.139. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 3.139. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD3.254MRQ3.139+0.115
MRQ3.139TTM3.1390.000
TTM3.139YOY-5.284+8.423
TTM3.1395Y-11.601+14.740
5Y-11.60110Y-10.381-1.220
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.254-3.007+6.261
MRQ3.139-2.704+5.843
TTM3.139-3.627+6.766
YOY-5.284-4.334-0.950
3Y-1.351-5.070+3.719
5Y-11.601-8.532-3.069
10Y-10.381-9.305-1.076
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Compugen is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.83 means the investor is paying 2.83Β for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of Compugen:

  • The EOD is 2.932. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.829. Based on the equity, the company is underpriced. +1
  • The TTM is 2.829. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.932MRQ2.829+0.103
MRQ2.829TTM2.8290.000
TTM2.829YOY2.906-0.078
TTM2.8295Y3.815-0.986
5Y3.81510Y6.481-2.666
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.9321.921+1.011
MRQ2.8291.843+0.986
TTM2.8292.113+0.716
YOY2.9062.467+0.439
3Y2.1982.541-0.343
5Y3.8153.666+0.149
10Y6.4814.311+2.170
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets114,995
Total Liabilities60,081
Total Stockholder Equity54,914
 As reported
Total Liabilities 60,081
Total Stockholder Equity+ 54,914
Total Assets = 114,995

Assets

Total Assets114,995
Total Current Assets105,997
Long-term Assets8,998
Total Current Assets
Cash And Cash Equivalents 18,229
Short-term Investments 85,026
Total Current Assets  (as reported)105,997
Total Current Assets  (calculated)103,255
+/- 2,742
Long-term Assets
Property Plant Equipment 3,695
Long-term Assets Other 343
Long-term Assets  (as reported)8,998
Long-term Assets  (calculated)4,038
+/- 4,960

Liabilities & Shareholders' Equity

Total Current Liabilities20,160
Long-term Liabilities39,921
Total Stockholder Equity54,914
Total Current Liabilities
Accounts payable 1,838
Total Current Liabilities  (as reported)20,160
Total Current Liabilities  (calculated)1,838
+/- 18,322
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,912
Long-term Liabilities  (as reported)39,921
Long-term Liabilities  (calculated)2,912
+/- 37,009
Total Stockholder Equity
Total Stockholder Equity (as reported)54,914
Total Stockholder Equity (calculated)0
+/- 54,914
Other
Capital Stock248
Common Stock Shares Outstanding 89,541
Net Invested Capital 54,914
Net Working Capital 85,837
Property Plant and Equipment Gross 9,443



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
> Total Assets 
56,711
114,986
99,307
71,139
38,746
53,180
53,763
138,316
132,163
94,176
121,334
114,995
114,995121,33494,176132,163138,31653,76353,18038,74671,13999,307114,98656,711
   > Total Current Assets 
53,216
75,098
90,999
62,680
31,179
46,578
45,000
129,090
123,222
86,125
114,579
105,997
105,997114,57986,125123,222129,09045,00046,57831,17962,68090,99975,09853,216
       Cash And Cash Equivalents 
28,751
25,643
10,777
9,709
25,470
5,861
9,187
7,143
7,801
11,059
13,890
18,229
18,22913,89011,0597,8017,1439,1875,86125,4709,70910,77725,64328,751
       Short-term Investments 
22,580
48,196
69,993
50,825
3,918
39,209
34,040
116,622
109,248
72,287
36,795
85,026
85,02636,79572,287109,248116,62234,04039,2093,91850,82569,99348,19622,580
       Net Receivables 
1,229
58
8,311
75
34
109
35
2,000
57
85
61,000
0
061,00085572,0003510934758,311581,229
       Other Current Assets 
154
684
1,077
1,000
1,067
605
652
667
713
362
0
0
003627136676526051,0671,0001,077684154
   > Long-term Assets 
0
0
0
8,459
7,567
6,602
8,763
9,226
8,941
8,051
6,755
8,998
8,9986,7558,0518,9419,2268,7636,6027,5678,459000
       Property Plant Equipment 
1,208
2,730
6,028
5,965
4,647
3,372
5,585
4,483
3,905
3,358
2,545
3,695
3,6952,5453,3583,9054,4835,5853,3724,6475,9656,0282,7301,208
       Long Term Investments 
0
35,026
2,179
2,402
2,810
0
0
0
0
0
0
0
00000002,8102,4022,17935,0260
       Long-term Assets Other 
0
0
0
8,459
7,567
6,602
8,763
0
0
0
0
343
34300008,7636,6027,5678,459000
> Total Liabilities 
24,823
8,870
9,410
7,620
9,449
15,937
15,442
18,534
25,470
16,496
55,775
60,081
60,08155,77516,49625,47018,53415,44215,9379,4497,6209,4108,87024,823
   > Total Current Liabilities 
7,739
6,589
6,854
4,740
6,194
9,989
6,819
10,523
17,096
11,919
26,266
20,160
20,16026,26611,91917,09610,5236,8199,9896,1944,7406,8546,5897,739
       Accounts payable 
693
1,493
2,001
1,274
3,445
2,946
1,088
1,413
4,621
1,773
3,502
1,838
1,8383,5021,7734,6211,4131,0882,9463,4451,2742,0011,493693
       Other Current Liabilities 
5,323
2,517
1,687
4
0
1,089
774
668
3,629
325
0
0
003253,6296687741,089041,6872,5175,323
   > Long-term Liabilities 
0
0
0
2,880
3,255
5,948
8,623
8,011
8,374
4,577
29,509
39,921
39,92129,5094,5778,3748,0118,6235,9483,2552,880000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
3,578
3,166
2,750
1,925
1,351
2,912
2,9121,3511,9252,7503,1663,578000000
> Total Stockholder Equity
31,888
106,116
89,897
63,519
29,297
37,243
38,321
119,782
106,693
77,680
65,559
54,914
54,91465,55977,680106,693119,78238,32137,24329,29763,51989,897106,11631,888
   Common Stock
111
137
138
140
140
164
187
231
239
240
0
0
00240239231187164140140138137111
   Retained Earnings Total Equity000000000000
   Accumulated Other Comprehensive Income 000000000000
   Capital Surplus 000000000000
   Treasury Stock000000000000
   Other Stockholders Equity 
4,628
1,222
421
7
17
0
0
0
0
0
0
0
00000001774211,2224,628



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue27,864
Cost of Revenue-7,930
Gross Profit19,93419,934
 
Operating Income (+$)
Gross Profit19,934
Operating Expense-42,755
Operating Income-14,891-22,821
 
Operating Expense (+$)
Research Development24,810
Selling General Administrative10,015
Selling And Marketing Expenses-
Operating Expense42,75534,825
 
Net Interest Income (+$)
Interest Income3,489
Interest Expense--
Other Finance Cost-1,713
Net Interest Income5,202
 
Pretax Income (+$)
Operating Income-14,891
Net Interest Income5,202
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-9,709-14,871
EBIT - interestExpense = 0
-14,231
-14,231
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--9,709
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-9,709
Tax Provision-4,522
Net Income From Continuing Ops-14,231-14,231
Net Income-14,231
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-20-5,202
 

Technical Analysis of Compugen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Compugen. The general trend of Compugen is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Compugen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Compugen Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Compugen.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 628.20 < 638.00 < 750.00.

The bearish price targets are: 443.00 > 442.80 > 319.40.

Know someone who trades $CGEN? Share this with them.πŸ‘‡

Compugen Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Compugen. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Compugen Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Compugen.

Compugen Daily Moving Average Convergence/Divergence (MACD) ChartCompugen Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Compugen. The current adx is .

Compugen Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Compugen.

Compugen Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Compugen.

Compugen Daily Relative Strength Index (RSI) ChartCompugen Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Compugen.

Compugen Daily Stochastic Oscillator ChartCompugen Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Compugen.

Compugen Daily Commodity Channel Index (CCI) ChartCompugen Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Compugen.

Compugen Daily Chande Momentum Oscillator (CMO) ChartCompugen Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Compugen.

Compugen Daily Williams %R ChartCompugen Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Compugen.

Compugen Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Compugen.

Compugen Daily Average True Range (ATR) ChartCompugen Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Compugen.

Compugen Daily On-Balance Volume (OBV) ChartCompugen Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Compugen.

Compugen Daily Money Flow Index (MFI) ChartCompugen Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Compugen.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-03MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Compugen Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Compugen based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose584.400
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Compugen with someone you think should read this too:
  • Are you bullish or bearish on Compugen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Compugen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Compugen

I send you an email if I find something interesting about Compugen.


Comments

How you think about this?

Leave a comment

Stay informed about Compugen.

Receive notifications about Compugen in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.